Navigation Links
ESF's workshop restores good name of sugar
Date:1/17/2008

Sugars were once credited with magical healing powers but are now seen like salt as an evil necessary in small doses but the cause of numerous diseases such as diabetes if taken in excess. Yet latest research suggests this view ignores the vital role played by more complex sugars in many biological structures, and the great therapeutic potential they have.

This all emerged in a recent workshop organised by the European Science Foundation (ESF) on the current state of the art in glycoscience, the study of complex sugars in biology. Delegates heard how glycoscience has become one of the hotbeds of biological and medical research, intimately involved in every aspect of metabolism and immune function. The big challenge now is to coordinate research in the field, bring together the relevant specialisms, and determine where to go next, according to the ESF workshops convenor, Tony Merry from Manchester University in the UK. There is so much progress in the field it is a bit difficult to predict where the greatest impact will be, said Merry.

The key point is that complex sugars are involved every time cells, and smaller structures within cells, communicate or bind with each other. This means they play a major part in all processes, including immune recognition and brain functions such as memory. It also means complex carbohydrates are often implicated in diseases where these functions go wrong, including auto-immune disorders such as multiple sclerosis and rheumatoid arthritis, as well as some cancers. The immune response often depends on the identity and location of sugars on antigens, which are the surface molecules on pathogens such as bacteria, or in principle any cells or smaller biological components such as protein complexes, that are recognised by the bodys own machinery for detecting foreign bodies. Complex sugars such as polysaccharides are core components of antigens, alongside lipids (fatty compounds) and proteins. These antigens in effect determine the outcome of an infectious disease and the response by the host organism such as human - structural differences between these antigens often account for the inability of many diseases to cross from one animal species to another and this is exemplified in the case of influenza where key molecules on the virus interacty with different complex sugars in birds and humans.

The ESF workshop identified the need to build momentum behind glycoscience, whose importance has been grossly undervalued, and in particular to boost European research. We decided that we need to all speak with one voice through a single organisation in Europe so we have agreed to expand the UK based Glycoscience Forum, of which I am Executive Secretary, to become the Euroglycosciences Forum. We also decided this should be reflected by recruitment of members throughout Europe onto committees, said Merry. We agreed that although we have world class expertise in many areas (and if fact are world leaders in some) we do not have the same presence and image as has been forged by our colleagues in USA and Japan.

Equally the profile of the field needs boosting not just among the public, but also within the scientific community, which has tended to downplay the importance of glycoscience partly because it seems too complicated to understand and analyse. The chemistry of glycoscience is extremely difficult, Merry admitted. But it is possible to simplify the chemistry and define it in terms of essential active constituents and interactions, as has been done for DNA and proteins, which are built up from more straightforward components, respectively nucleic acids and amino acids. According to Merry a similar rationalisation is needed for carbohydrates to bring glycomics the science of sugars in general onto the same footing as genomics (genes) and proteomics (proteins).

It is vital that this task is achieved since glycomics, genomics and proteomics are all equal cogs in the overall mechanism of biology, to the extent that progress in developing therapies depends on integrating the three together rather than advancing on one front while ignoring another.

The ESF Exploratory Workshop, Glycoscience Comes Of Age, was held at Kolocep, Croatia, in May 2007. The stage was set for a coordinated but flexible European glycoscience programme mediated by a forum of members from a number of different disciplines.


'/>"/>

Contact: Dr. Tony Merry
Anthony.Merry@manchester.ac.uk
44-016-088-11022
European Science Foundation
Source:Eurekalert

Related biology news :

1. Workshops on biotechnology and water for science journalists
2. Hybridization partially restores vision in cavefish, NYU study finds
3. Study of sugars on cell surface identifies key factor in flu infection
4. Cornell researchers prove how plants transport sugars
5. Too much fructose could leave dieters sugar shocked
6. Too much sugar turns off gene that controls the effects of sex steroids
7. The accumulation of sugar in neurons may explain the origin of several neurodegenerative diseases
8. Sugary drinks, not fruit juice, may be linked to insulin
9. Right breakfast bread keeps blood sugar in check all day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new study published in ... previously treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute ... of blood sampling may improve the value of a blood-based test.” The study ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
Breaking Biology Technology: